WGWen-Xi Gao

Wen-Xi Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wen-Xi Gao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Chiwei Chen

    Affiliations The Research Center of Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China, Department of Urology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China

    1 shared publication
  • Chun-He Zhang

    Yunnan Provincial Hospital of Traditional Chinese Medicine, Yunnan, 650021, People's Republic of China

    1 shared publication
  • Danhui Yi

    School of Statistics, Renmin University of China, Beijing, China

    1 shared publication
  • Guohao Li

    Affiliation Department of Urology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei University of Chinese Medicine Affiliated Hubei Hospital of Chinese Medicine, Wuhan, Hubei, China

    1 shared publication
  • Jian Lyu

    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    1 shared publication
  • Jian-Wu Shen

    Department of Urology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma

    by Renlun Huang, Lang Guo, Chiwei Chen, Yuyang Xiang, Guohao Li, Jieyan Zheng, Yanping Wu, Xiu Yuan, Jianfu Zhou, Wenxi Gao, et al.

    Ubiquitin Conjugating Enzyme 2C (UBE2C) is an emerging target gene for tumor progression. However, the tumorigenic effect and mechanism of UBE2C in adrenocortical carcinoma (ACC) remains unclear. Systematic investigation of the tumorigenic effect of UBE2C may help in understanding its prognostic value in adrenocortical carcinoma. First, we exploited the intersection on DFS-related genes, OS-related genes, highly expressed genes in adrenocortical carcinoma as well as differentially expressed genes (DEGs) between tumor and normal, and then obtained 20 candidate genes. UBE2C was identified to be the most significant DEG between tumor and normal. It is confirmed that high expression of UBE2C was strongly associated with poor prognosis in patients with ACC by analyzing RNA-seq data of ACC obtained from the Cancer Genome Atlas (TCGA) database implemented by ACLBI Web-based Tools. UBE2C expression could also promote m6A modification and stemness in ACC. We found that UBE2C expression is positively associated with the expression of CDC20, CDK1, and CCNA2 using ACLBI Web-based Tools, indicated the hyperactive cell cycle progression present in ACC with high UBE2C expression. In addition, UBE2C knockdown could significantly inhibit the proliferation, migration, invasion, EMT of adrenocortical carcinoma cells as well as the cell cycle progression in vitro. Notably, pan-cancer analysis also identified UBE2C as an oncogene in various tumors. Taken together, UBE2C was strongly associated with poor prognosis of patients with ACC by promoting cell cycle progression and EMT. This study provides a new theoretical basis for the development of UBE2C as a molecular target for the treatment of ACC.


  • Open Access

    Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial

    by Jian Lyu, Yan-Ming Xie, Zhan Gao, Jian-Wu Shen, Yue-Yi Deng, Song-Tao Xiang, Wen-Xi Gao, Wen-Tong Zeng, Chun-He Zhang, Dan-Hui Yi, et al.

    Acute uncomplicated lower urinary tract infection (UTI) is one of the most common bacterial infections. Patients usually present with dysuria, urinary urgency, urinary frequency, and suprapubic pain or tenderness. Approximately 150 million people are diagnosed with UTI each year worldwide. The high recurrence rate of lower UTI is a common problem of clinical treatment. The misuse of antibiotics has led to the emergence of a number of resistant bacterial strains. Thus, traditional Chinese medicine is considered as an alternative option for treating acute uncomplicated lower UTI. Thus, this study aims to evaluate the efficacy and safety of Sanjin tablets (SJT) for the treatment of acute uncomplicated lower UTI, explore whether SJT can reduce or substitute the use of antibiotics, and reduce the recurrence rate in the treatment of acute uncomplicated lower UTI. In this study, a randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical study will be established. A total of 252 patients with acute uncomplicated lower UTI (syndrome of dampness-heat in the lower jiao) will be randomly allocated in the ratio of 1:1:1 to three groups: experimental group; control group 1; and control group 2. The experimental group receives Sanjin tablets plus levofloxacin tablets (LT) placebo; the control group 1 receives LT plus SJT placebo; and the control group 2 receives SJT plus LT on the first five days, SJT plus LT placebo on the last two days. Each group will be treated for seven days and followed-up 1–2 times. The primary outcome measures of effective rate and recurrence rate are symptoms. Secondary outcome measures of effective rate and recurrence rate are the urine leukocytes, bacteriology examination, and safety assessment. Outcomes will be assessed at baseline and after treatment. This study protocol will provide the research data of efficacy and safety of SJT for the treatment of acute uncomplicated lower UTI. The first aim is to determine whether Sanjin tablets can reduce the use of antibiotics; the second aim is to determine whether Sanjin tablets can substitute the use of antibiotics. The recurrence rate will be assessed after cured to determine whether SJT can reduce the recurrence rate. The results of this study will improve the rational use of drugs, especially the rational application of antibiotics. It will also enable safety evaluation from laboratory indices and adverse events, which will provide reliable evidence for clinical treatment. ClinicalTrials.gov, NCT03658291 . Registered on 4 September 2018.